Skip to content

Study · Animal study (in vivo) · rat · 2021

3 results

BPC 157 as a Therapy for Retinal Ischemia Induced by Retrobulbar Application of L-NAME in Rats.

Zlatar M, Kokot A, Vuletic LB, Masnec S, Kralj T, Perisa MM, Barisic I, Radic B, Milanovic K, Drmic D, Seiwerth S, Sikiric P

Frontiers in pharmacology10 Jun 2021Cited by 15 (Europe PMC)

Summary

Providing NO-system importance, we suggest that one single application of the NOS-blocker L-NAME may induce retinal ischemia in rats, and that the stable pentadecapeptide BPC 157 may be the therapy, since it may interact with the NO-system and may counteract various adverse effects of L-NAME application. A rat retinal ischemia study was conducted throughout 4 weeks, including fundoscopy, behavior presentation, tonometry, and histology assessment. Retrobulbar L-NAME application (5 mg/kg; 0.5 mg/0.1 ml saline/each eye) in rats immediately produced moderate generalized irregularity in the diameter of blood vessels with moderate atrophy of the optic disc and faint presentation of the choroidal blood vessels, and these lesions rapidly progressed to the severe stage. The specific L-NAME-induced vascular failure points to normal intraocular pressure (except to very transitory increase upon drug retrobulbar administration). When BPC 157 (10 μg; 10 ng/kg, as retrobulbar application, 1 μg; 1 ng/0.1 ml saline/each eye) is given at either 20 min after L-NAME or, lately, at 48 h after L-NAME, the regular retrobulbar L-NAME injection findings disappear. Instead, fundoscopy demonstrated only discrete generalized vessel caliber irregularity with mild atrophy of the optic disc, and then, quite rapidly, normal eye background and choroidal blood vessels, which remain in all of the subsequent periods. Also, histology assessment at 1, 2, and 4 weeks shows that BPC 157 counteracted the damaged inner plexiform layer and inner nuclear layer, and revealed normal retinal thickness. The poor behavioral presentation was also rescued. Thus, while further studies will be done, BPC 157 counteracted L-NAME-induced rat retinal ischemia.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with L-NAME-induced retinal ischemia, retrobulbar BPC‑157 given at 20 min or 48 h after L-NAME made the L-NAME findings disappear, leaving only discrete vessel irregularity and mild optic disc atrophy, then a normal eye background.

    In plain wordsIn rats with induced eye ischemia, BPC‑157 given early or late made the eye damage signs disappear.

    Peptide
    BPC-157
    Outcome
    DecreaseFundoscopy findings after L-NAME (vessel caliber, optic disc atrophy)
    Study

    ratn: not reported in source

    Retrobulbar L-NAME-induced retinal ischemia
    Comparator
    L-NAME without BPC 157
    Outcome group
    Neuroprotection · Eye
    Studied dose
    10 μg; 10 ng/kg (1 μg; 1 ng/0.1 ml saline per eye) · retrobulbarAs given in this study (rat).

    Source sentences

    Summary
    When BPC 157 (10 μg; 10 ng/kg, as retrobulbar application, 1 μg; 1 ng/0.1 ml saline/each eye) is given at either 20 min after L-NAME or, lately, at 48 h after L-NAME, the regular retrobulbar L-NAME injection findings disappear.
    2 context sentences
    Summary · context
    Instead, fundoscopy demonstrated only discrete generalized vessel caliber irregularity with mild atrophy of the optic disc, and then, quite rapidly, normal eye background and choroidal blood vessels, which remain in all of the subsequent periods.
    Summary · context
    A rat retinal ischemia study was conducted throughout 4 weeks, including fundoscopy, behavior presentation, tonometry, and histology assessment.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with L-NAME-induced retinal ischemia, BPC‑157 counteracted damage to the inner plexiform layer and inner nuclear layer and gave normal retinal thickness.

    In plain wordsIn rats with induced eye ischemia, BPC‑157 counteracted retinal layer damage and kept retinal thickness normal.

    Peptide
    BPC-157
    Outcome
    DecreaseRetinal histology at 1, 2 and 4 weeks
    Study

    ratn: not reported in source

    Retrobulbar L-NAME-induced retinal ischemia
    Comparator
    L-NAME without BPC 157
    Outcome group
    Neuroprotection · Eye
    Studied dose
    10 μg; 10 ng/kg (1 μg; 1 ng/0.1 ml saline per eye) · retrobulbarAs given in this study (rat).

    Source sentences

    Summary
    Also, histology assessment at 1, 2, and 4 weeks shows that BPC 157 counteracted the damaged inner plexiform layer and inner nuclear layer, and revealed normal retinal thickness.
    1 context sentence
    Summary · context
    A rat retinal ischemia study was conducted throughout 4 weeks, including fundoscopy, behavior presentation, tonometry, and histology assessment.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with L-NAME-induced retinal ischemia, BPC‑157 rescued the poor behavioral presentation.

    In plain wordsIn rats with induced eye ischemia, BPC‑157 rescued the poor behavior seen after the damage.

    Peptide
    BPC-157
    Outcome
    IncreaseBehavioral presentation
    Study

    ratn: not reported in source

    Retrobulbar L-NAME-induced retinal ischemia
    Comparator
    L-NAME without BPC 157
    Outcome group
    Neuroprotection · Eye
    Studied dose
    10 μg; 10 ng/kg (1 μg; 1 ng/0.1 ml saline per eye) · retrobulbarAs given in this study (rat).

    Source sentences

    Summary
    The poor behavioral presentation was also rescued.
    1 context sentence
    Summary · context
    A rat retinal ischemia study was conducted throughout 4 weeks, including fundoscopy, behavior presentation, tonometry, and histology assessment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.